Navigation

Asthma (in children) - omalizumab

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11

Status: History
Expected date of issue: September 2010
Referral date: September 2009
Process: STA
Notes:

Scoped within batch 8

Topic area:
  • Respiratory
 

NICE project team

Executive Lead: Gill Leng
Technical Lead: Helen Tucker
Communications manager: Katie Williamson
Project manager: Jeremy Powell
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 28 January 2010
1st appraisal committee meeting: 05 May 2010
2nd appraisal committee meeting 01 July 2010
Top


 

Consultees and commentators

Consultees Commentators (no right of appeal)

Manufacturers / Sponsors

  • Novartis

Patient / Carer Groups

  • Allergy UK
  • Asthma UK

Professional groups

  • British Society for Allergy & Clinical Immunology
  • British Thoracic Society
  • Primary Care Respiratory Society UK
  • Royal College of Nursing
  • Royal College of Paediatrics & Child Health
  • Royal College of Pathologists
  • Royal College of Physicians
  • Royal Pharmaceutical Society

Others

  • Department of Health
  • NHS Gloucestershire
  • Welsh Assembly Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • NHS Quality Improvement Scotland

Comparator manufacturer(s)

  • Actavis (salbutamol, terbutaline) - no confidentiality form - removed
  • Arrow Generics (salbutamol) - no confidentiality form - removed
  • AstraZeneca (terbutaline)
  • Boehringer Ingelheim (ipratroprium bromide, salbutamol)
  • Chiesi (salbutamol) - no confidentiality form - removed
  • Doncaster Pharmaceuticals (montelukast, salbutamol, terbutaline) - no confidentiality form - removed
  • GlaxoSmithKline (ipratroprium bromide, salbutamol)
  • Kent Pharmaceuticals (salbutamol) - no confidentiality form - removed
  • Meda Pharmaceuticals (salbutamol, theophylline) - no confidentiality form - removed
  • Merck Serono (theophylline) - no confidentiality form - removed
  • Merck Sharp & Dohme (montelukast)
  • Napp Pharmaceuticals Ltd (theophylline)
  • Pinewood Healthcare (salbutamol) - no confidentiality form - removed
  • Sandoz (salbutamol, terbutaline) - no confidentiality form - removed
  • sanofi aventis (theophylline) - No confidentiality form - removed
  • Sigma Pharmaceuticals (ipratroprium bromide, montelukast, salbutamol, terbutaline) - no confidentiality form - removed
  • Sinclair Pharmaceuticals (salbutamol) - no confidentiality form - removed
  • Teva UK (ipratroprium bromide, salbutamol) - no confidentiality form - removed
  • Waymade (ipratroprium bromide, montelukast, salbutamol, terbutaline) - no confidentiality form - removed

Relevant research groups

  • Cochrane Airways Group

Evidence Review Group

  • Centre for Reviews and Dissemination, University of York (CRD)

Associated Guideline Groups

  • National Collaborating Centre for Women and Children’s Health

Associated Public Health Groups

  • None

Top


 

Key documents

This page was last updated: 27 October 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.